Show summary Hide summary
- Study reveals link between GLP-1 drugs and Wernicke encephalopathy
- Why GLP-1 drugs can trigger a vitamin B1 shortfall
- Recognizing Wernicke encephalopathy: symptoms and diagnostic challenges
- Who is already at elevated risk for thiamine deficiency?
- Practical signs for clinicians and patients to watch while on GLP-1 therapy
As millions turn to GLP-1 injections to lose weight, researchers have raised alarms about a rare but serious brain disorder linked to two popular drugs. New findings suggest a chain of effects from nausea and poor eating to a vitamin shortfall that can lead to lasting brain injury.
Study reveals link between GLP-1 drugs and Wernicke encephalopathy
Heart disease risk: does belly fat beat BMI as a predictor?
GLP-1 drugs may cause rare, deadly brain disorder: study warns
A team in Israel analyzed nearly 196,000 reports and identified a small cluster of Wernicke encephalopathy cases among users of incretin-based weight-loss medicines. Semaglutide and tirzepatide stood out in the review.
Those medicines are marketed under familiar names, including Ozempic, Wegovy, Rybelsus, Mounjaro and Zepbound. The investigators found that cases of the brain disorder were more common with these drugs than with many other treatments.
Researchers noted that many affected patients had ongoing gastrointestinal troubles that reduced calorie and nutrient intake. The team called the event rare but urged clinicians to remain vigilant.
Why GLP-1 drugs can trigger a vitamin B1 shortfall
GLP-1 medications slow stomach emptying and blunt appetite. That effect helps people eat less and lose weight.
But prolonged nausea, vomiting or poor food intake can cause deficiencies.
The role of thiamine in the brain
Thiamine, or vitamin B1, is essential for how brain cells make energy. Without it, nerve cells can fail and key brain regions can swell.
Insufficient thiamine can progress to Wernicke encephalopathy. The connection stems from the combined effect of reduced intake and impaired absorption.
Recognizing Wernicke encephalopathy: symptoms and diagnostic challenges
The classic warning signs include altered thinking, walking problems, and abnormal eye movements.
- Altered mental state or confusion
- Gait instability or difficulty walking
- Loss of coordinated eye movement
But only a small fraction of patients show all three signs at once. Many cases are subtle and mimic other conditions, such as intoxication or dementia. That makes diagnosis difficult and leads to many missed cases.
When detected early, high-dose thiamine given intravenously can halt further brain injury. Delay in treatment carries a high risk: untreated illness can be fatal, and survivors often have permanent deficits.
Who is already at elevated risk for thiamine deficiency?
Some groups have long been known to face greater danger of thiamine loss:
- People with chronic alcohol use, due to poor absorption and storage
- Patients after bariatric surgery, who may absorb fewer nutrients
- Individuals with severe eating disorders such as anorexia
- Cases of prolonged vomiting, including syndromes tied to heavy cannabis use
Adding GLP-1–related nausea and reduced intake can tip vulnerable people into a dangerous deficiency.
Practical signs for clinicians and patients to watch while on GLP-1 therapy
Clinicians should consider thiamine deficiency when patients on these drugs report significant weight loss or persistent GI symptoms.
- Monitor for ongoing vomiting and inadequate nutrition
- Ask about balance problems, confusion, or vision changes
- Consider early thiamine testing or empiric supplementation in high-risk cases
Prompt recognition and treatment can prevent permanent harm. Patients experiencing concerning symptoms should seek medical evaluation without delay.
